Effectiveness of Intraoperative Exparel for Postoperative Pain Control in Total Knee Arthroplasty
Launched by DECLAIRE LAMACCHIA ORTHOPAEDIC INSTITUTE · Jun 17, 2016
Trial Information
Current as of May 21, 2025
Unknown status
Keywords
ClinConnect Summary
The investigators use a double blind, controlled, randomized study to examine the effectiveness of periarticular Exparel in total knee arthroplasty postoperative pain control as well as effect on early mobilization and length of hospital stay when compared to another local analgesic (Ropivacaine) when both are used as part of a multimodal pain management approach.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patient undergoing Total Knee Arthroplasty with Dr. J.H. DeClaire
- • 18 years of age or older
- • Primary diagnosis of osteoarthritis of the knee
- • Opioid naïve patient (according to FDA guidelines)
- Exclusion Criteria:
- • Prior knee replacement
- • Prior use of narcotics for chronic pain management
- • Inflammatory arthritis (Rheumatoid arthritis, Lupus, etc.)
- • Unicompartmental knee replacement
- • Bilateral Total Knee Arthroplasty
- * Opioid Tolerant as defined by the FDA: Patients who are taking, for one week or longer, at least:
- • \> 60 mg oral morphine/day \> 25μg transdermal fentanyl/hour \> 30 mg oral oxycodone/day \> 8 mg oral hydromorphone/day \> 25 mg oral oxymorphone/day
About Declaire Lamacchia Orthopaedic Institute
Declaire Lamacchia Orthopaedic Institute is a renowned clinical research organization dedicated to advancing orthopedic care through innovative clinical trials. With a focus on enhancing patient outcomes and developing cutting-edge treatments, the institute collaborates with leading medical professionals and research institutions. Its commitment to rigorous scientific methodology and ethical standards ensures the safety and efficacy of new therapies. By leveraging state-of-the-art technology and a patient-centered approach, Declaire Lamacchia Orthopaedic Institute aims to contribute significantly to the field of orthopedics and improve the quality of life for patients globally.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Olayinka Warritay, MD
Study Director
DeClaire LaMacchia Orthopaedic Institute
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials